Key Insights

Private equity firms have a significant ownership stake in IO Biotech, giving them a greater say in the company’s management and business strategy. With a total of 5 investors holding a majority stake of 54%, it is clear that these firms have a strong influence on the direction of the company. Institutional ownership in IO Biotech stands at 22%, indicating a level of credibility in the investment community.

The top 5 shareholders collectively own 54% of the company, with private equity firms holding the largest share at 59%. This ownership structure suggests that these shareholders have a meaningful say in the decisions of the company. While hedge funds do not have a significant investment in IO Biotech, Lundbeckfonden BioCapital is the largest shareholder with a 21% stake.

Insider ownership of IO Biotech is under 1%, with board members holding a minimal amount of shares in the company. The general public holds a 19% stake, while private equity firms maintain a 59% ownership. This level of private equity ownership indicates their potential influence on key policy decisions within the company.

Investors interested in IO Biotech should consider the various ownership groups and factors affecting the company’s performance. It is important to conduct thorough research and analysis before making investment decisions.